09.24.14
Catalent Pharma Solutions has reached an exclusive development and licensing agreement with Cingulate Therapeutics (CTx) to support formulation development of a series of new drug products to treat Attention Deficit/Hyperactivity Disorder (ADHD) using Catalent’s OSDrC OptiDose drug delivery platform.
The products, CTX-1301 and CTX-1302, are currently in preclinical development and are designed to address several unmet patient needs with ADHD. The company’s lead product, CTX-1301, is expected to complete Phase I/Phase II trials in early 2015. Cingulate aims to develop and commercialize the CTx products in the U.S., followed by the EU and other strategic markets.
Catalent’s OSDrC OptiDose is a flexible core tableting technology that enables the formulation and manufacture of single or multi-cored tablets with differentiated controlled release functionality in a range of dose forms, including fixed dose combination tablets.
“OptiDose enables the design of dividable, multi-layer, single or multi-core tablets with a variety of core numbers, shapes, sizes, and placement, providing new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing process,” said Barry Littlejohns, president of Advanced Delivery Technologies for Catalent. “We are excited to be working with Cingulate Therapeutics to bring these important treatments to market as quickly and efficiently as possible.”
“Cingulate Therapeutics is proud to partner with Catalent in developing these innovative therapies, designed to overcome longstanding unmet needs in ADHD,” added Shane Schaffer, chairman and chef executive officer of Cingulate Therapeutics. “The precision engineered, cutting-edge technology and strong patent protection inherent to OptiDose, coupled with Catalent’s unparalleled expertise in drug formulation, provides Cingulate Therapeutics great confidence in its overall ability to deliver safe, effective and innovative treatment options to clinicians and patients alike.”
The products, CTX-1301 and CTX-1302, are currently in preclinical development and are designed to address several unmet patient needs with ADHD. The company’s lead product, CTX-1301, is expected to complete Phase I/Phase II trials in early 2015. Cingulate aims to develop and commercialize the CTx products in the U.S., followed by the EU and other strategic markets.
Catalent’s OSDrC OptiDose is a flexible core tableting technology that enables the formulation and manufacture of single or multi-cored tablets with differentiated controlled release functionality in a range of dose forms, including fixed dose combination tablets.
“OptiDose enables the design of dividable, multi-layer, single or multi-core tablets with a variety of core numbers, shapes, sizes, and placement, providing new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing process,” said Barry Littlejohns, president of Advanced Delivery Technologies for Catalent. “We are excited to be working with Cingulate Therapeutics to bring these important treatments to market as quickly and efficiently as possible.”
“Cingulate Therapeutics is proud to partner with Catalent in developing these innovative therapies, designed to overcome longstanding unmet needs in ADHD,” added Shane Schaffer, chairman and chef executive officer of Cingulate Therapeutics. “The precision engineered, cutting-edge technology and strong patent protection inherent to OptiDose, coupled with Catalent’s unparalleled expertise in drug formulation, provides Cingulate Therapeutics great confidence in its overall ability to deliver safe, effective and innovative treatment options to clinicians and patients alike.”